Recent studies have shown good responses to a selective pan‐AKT inhibitor in phase I/II open‐label study in advanced solid malignancies, including breast and gynecologic cancers, with PIK3CA mutations.31, 32 Another investigation demonstrated the potential promise of combined MEK and MDM2 inhibitors for treating KRAS‐mutant nonsmall cell lung cancer and colorectal cancer.33 This evidence concerns the gene MAP2K7 and female reproductive organ cancer.